GSK Sees Shingles Market Growth to 2036 as New Vaccines Enter Phase II
Herpes zoster market projected to expand through 2036, supporting GSK’s SHINGRIX franchise while emerging vaccines CRV-101 and JCXH-105 enter Phase II. GSK’s Specialty Medicines arm reported rising HIV, respiratory and oncology sales but vaccine unit sales declined due to generic competition.
1. Shingles Market Outlook
The herpes zoster market is forecast to grow through 2036, driven by rising incidence in aging populations and increased vaccine adoption. SHINGRIX remains the current standard while pipeline candidates CRV-101 and JCXH-105 advance into Phase II trials, potentially reshaping competitive dynamics.
2. Specialty Medicines Performance
GSK’s Specialty Medicines unit reported increased sales in HIV, respiratory and oncology segments, offsetting pressures from generic competition in other areas. However, the Vaccines segment experienced sales declines, underscoring uneven performance across GSK’s business units.